Martin Shkreli violated lifetime pharma industry ban, FTC and states say

Federal regulators seek to hold Martin Shkreli in contempt for violating his lifetime pharmaceutical industry ban via stock trading. The FTC and seven states request fines equal to his profits from pharma stocks since February 2022.